Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

inical trials; reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:9/1/2014)... 2014 The National Association of Hispanic ... Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, ... Academy of Nursing. They will be inducted with Immediate ... whose induction we reported last May. , Our three ... the 2014 American Academy of Nursing Policy Conference in ...
(Date:9/1/2014)... 01, 2014 Bioinformatics refers to ... analyze biological and genetic data. A major part ... developing software tools to generate and process useful ... with biological computation. While bioinformatics simply makes use ... can its related concepts, biological computation refers to ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... in September, where issues related to claims involving the ... of Pennsylvania, Bernstein Liebhard LLP reports. , According ... Court’s website, the meeting is scheduled to take place ... the latest of several Tylenol conferences that have taken ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web ... carefully, Top10BestSEOHosting.com is here to announce that JustHost, ... suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) ... shared hosting plan. The company’s approach to hosting ... affordable, accessible and powerful enough for anyone to ...
(Date:9/1/2014)... Colorado (PRWEB) August 31, 2014 Daily ... an online resource and community that gives members access ... editing resources. , This online resource aims to help ... as well as artists who are looking for inspiration ... Learn more about Tattoo Me Now by visiting the ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Atopy (Allergy) Research Center at the Juntendo University School ... their fecal droppings// disrupt immune system in human skin ... ,Episodes of asthma and eczemas have been ... by other researchers. However the present study conducted in ...
... one of the greatest challenges facing researchers today, and recent ... a growing epidemic.// The World Health Organization has estimated that ... problems, of them nearly 300 million are obese. ... works on the source of the problem – appetite, the ...
... with breast cancer positive to hormone receptors and HER2 ... (anastrozole) from AstraZeneca to their treatment improves the length ... Phase III clinical trial sponsored by Roche showed that ... after which the cancer continued to progress. ...
... more people in the Indian capital Tuesday, taking the total ... situation did not warrant declaring it an epidemic. ,"We ... are well equipped to deal with the situation, hence there ... Minister Yoganand Shastri. ,At an emergency cabinet meeting ...
... specific class of antioxidants found in fruit and vegetable ... ,Non-vitamin antioxidants - polyphenols - are abundant in the ... also present in teas and wines. ,Lab ... potent effect on health, with the potential to significantly ...
... risk of coronary heart diseases, say experts."Coronary heart diseases (CHD) ... oil can reduce the risk of CHD," said S.C. Manchanda//, ... India Institute of Medical Sciences (AIIMS). ,Mustard oil ... the lowest amount of saturated fatty acids and a high ...
Cached Medicine News:Health News:Brain behind the Brawn: Vital Molecule in the Brain Controls Appetite 2Health News:Dengue Outbreak in the Capital is not an Epidemic: Government 2Health News:Mustard Oil can Reduce the Risk of Heart Diseases 2
... AXIOM Artis dTC is a versatile solution ... cardiology department from preparation to diagnosis ... procedures. With AXIOM Artis dTC, your cath ... cardiology department that leaves you free to ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... Artis BC is a biplane ... architecture ideal for cardiological diagnostics ... ergonomic architecture enables you to ... to focus on:, Interventional ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
Medicine Products: